Across TCGA pan-cancer cohorts, MIR517C Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR517C data layer compared with 6 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MIR517C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR517C expression acts as an unfavorable survival marker.
SKCM are the cancer types where MIR517C Mutation most reproducibly stratifies survival.